Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients: A meta-analysis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 7, 2014, Pages 1387-1395

  Kong, Ling Na ^a   Qin, Bo ^a   Ma, Qian ^a   Li, Lin ^a   Yao, Yu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Genotype; HBeAg positive; Hepatitis B virus; Interferon; Meta analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA; VIRUS DNA; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG RESPONSE; GENETIC HETEROGENEITY; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HUMAN; META ANALYSIS; MOLECULAR PHYLOGENY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SEROCONVERSION; BIBLIOGRAPHIC DATABASE; GENETICS; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DATABASES, BIBLIOGRAPHIC; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; TREATMENT OUTCOME;

EID: 84904289237     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12559     Document Type: Article

References (34)

1. Aung MN, Leowattana W, Tangpukdee N, Kittitrakul C. Observation of genotype C infected chronic hepatitis B patients in clinical practice. J. Infect. Dev. Ctries 2011; 5: 882-889.
2. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 2006; 28: 112-125.
3. Liaw YF. Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int. 2011; 31 (Suppl. 1): 117-121.
4. Liaw YF, Kao JH, Piratvisuth T etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
5. Liver EAftSot. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
7. Fan HB, Guo YB, Zhu YF etal. Hepatitis b virus genotype B and high expression of interferon alpha receptor beta subunit are associated with better response to pegylated interferon alpha 2a in Chinese patients with chronic hepatitis B infection. Hepat. Mon. 2012; 12: 333-338.
8. Zhang Y, Wu Y, Ye S etal. The response to interferon is influenced by hepatitis B virus genotype in vitro and in vivo. Virus Res. 2013; 171: 65-70.
9. Fried MW, Shiffman ML, Reddy KR etal. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 975-982.
10. Chen CH, Lee CM, Hung CH etal. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients. J. Gastroenterol. Hepatol. 2011; 26: 461-468.
11. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J. Hepatol. 2000; 33: 998-1002.
12. Mao QG, Pan JS, Fang KN etal. Precise prediction model and simplified scoring system for sustained combined response to interferon-alpha. World J. Gastroenterol. 2010; 16: 3465-3471.
13. Shen JK, Hou JL, Pang XN, Yang H, Xu ZJ. Correlation of HBV genotypes to the therapeutic effect of PEG-interferon and the pathological changes of the liver of chronic hepatitis B patients. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28: 1217-1218.
14. Zhao H, Kurbanov F, Wan MB etal. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin. Infect. Dis. 2007; 44: 541-548.
15. Zou HB, Zhu LM, Zhao GM etal. The relationship between HBV genotypes and the efficacy of antiviral therapies in hepatitis B e antigen-positive patients. Zhonghua Gan Zang Bing Za Zhi 2007; 15: 425-427.
16. Cooksley WG, Piratvisuth T, Lee SD etal. Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. 2003; 10: 298-305.
17. Luo K, He H, Liu Z, Zhu Y, Mao Q, Liang W. No significant differences in histology and response to interferon treatment in hepatitis B carriers of genotypes C and recombinant B. J. Viral Hepat. 2007; 14: 419-425.
18. Phisalprapa P, Charatcharoenwitthaya P, Chainuwatti S etal. HBV genotype B is not associated with better response to peginterferon therapy compared with genotype C [Abstract]. J. Gastroenterol. Hepatol. 2012; 27 (Suppl. 5): 253.
19. Tangkijvanich P, Komolmit P, Mahachai V, Sa-nguanmoo P, Theamboonlers A, Poovorawan Y. Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. J. Clin. Virol. 2009; 46: 117-123.
20. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir. Ther. 2008; 13: 211-220.
21. Chu RH, Ma LX, Wang G, Shao LH. Influence of HLA-DRB1 alleles and HBV genotypes on interferon-alpha therapy for chronic hepatitis B. World J. Gastroenterol. 2005; 11: 4753-4757.
22. Hansen BE, Buster EH, Steyerberg EW, Lesaffre E, Janssen HL. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J. Med. Virol. 2010; 82: 1135-1142.
23. Ma JC, Wang LW, Li XJ, Liao YF, Hu XY, Gong ZJ. Relationship between HBV genotypes and anti-viral therapeutic efficacy of interferon-alpha. Hepatobiliary Pancreat. Dis. Int. 2007; 6: 166-171.
24. Piratvisuth T, Lau G, Chao YC etal. Sustained response to peginterferon alfa-2a (40kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol. Int. 2008; 2: 102-110.
25. Lau GK, Piratvisuth T, Luo KX etal. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-2695.
26. Wai CT, Chu CJ, Hussain M, Lok AS. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-1430.
27. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N. Engl. J. Med. 2004; 350: 1118-1129.
28. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26: 1338-1342.
29. Chan HL, Hui AY, Wong ML etal. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498.
30. Yu MW, Yeh SH, Chen PJ etal. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl Cancer Inst. 2005; 97: 265-272.
31. Sugauchi F, Orito E, Ichida T etal. Hepatitis B virus of genotype B with or without recombination with genotype C over the precore region plus the core gene. J. Virol. 2002; 76: 5985-5992.
32. Stroup DF, Berlin JA, Morton SC etal. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
33. Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral treatment influenced by hepatitis B virus genotype? J. Hepatol. 2010; 52: 441-449.
34. Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis. PLoS ONE 2013; 8: e65952.